Crescendo Biologics Funding: $70M Raised, Series B (2023)
Crescendo Biologics is based in Cambridge, United Kingdom. It has raised $70M in total funding. Latest round: Series B.
Crescendo Biologics funding overview
Crescendo Biologics is based in Cambridge, United Kingdom. Crescendo Biologics has raised $70M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in January 2023. The round record for Crescendo Biologics runs through 2023; nothing later has been disclosed. Investors on record include Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital and 1 others. 7 distinct backers are named across the disclosed rounds.
Crescendo Biologics at a glance
Total raised
$70M
Latest round
Series B
Latest round date
January 2023
Headquarters
Cambridge, United Kingdom
Notable investors
Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital, Kreos Capital
Frequently asked about Crescendo Biologics funding
How much has Crescendo Biologics raised?
Crescendo Biologics has raised $70M in total disclosed funding across the rounds on record.
Who has invested in Crescendo Biologics?
Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital are named among the investors backing Crescendo Biologics.
What was the latest Crescendo Biologics funding round?
The most recent disclosed round is a Series B, announced in January 2023.
Where is Crescendo Biologics based?
Crescendo Biologics is based in Cambridge, United Kingdom.
When did Crescendo Biologics last raise?
The last disclosed Crescendo Biologics round closed in January 2023 at Series B.
Crescendo Biologics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
